Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to slow cancer in the brain and spine

NCT ID NCT06984523

Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a precise type of radiation called VMAT for people whose cancer has spread to the lining of the brain and spine (leptomeningeal metastasis). The goal is to see if this approach can delay cancer growth in the central nervous system better than older radiation methods. Twenty adults with solid tumors will receive 10 sessions of targeted radiation. Researchers will track how long patients go without their cancer worsening in the brain or spine.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (VMAT craniospinal irradiation)
What this could lead to
If successful, this could offer a more effective radiation option for people with cancer spread to the brain and spine lining, potentially delaying disease progression.
What could go wrong
This is a small, early-phase study with only 20 participants and no comparison group. The results may not apply to all patients, and radiation can cause side effects like fatigue or neurological symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Solid tumor cancer primary with leptomeningeal metastases established radiographically and/or by CSF cytology 2. Candidate for radiation therapy for the treatment of leptomeningeal metastases 3. If patient had prior radiation, a treatment plan can be generated that will not exceed normal tissue tolerances 4. Patient must have reasonable systemic treatment options, as confirmed by their medical oncologist 5. Age ≥ 18 years old 6. Able to provide informed consent 7. Karnofsky Performance Scale (KPS) ≥ 60 8. Adequate hematologic baseline 1. Hemoglobin \> 8g/dL 2. Absolute neutrophil count \>1,000/mm3 3. Platelet count \> 100,000/mm3 9. Female subjects must either be of 1. Non-reproductive potential (over 60 years old, or without menses for at least 1 year without an alternative medical cause) 2. Have history of hysterectomy, bilateral tubal ligation, or bilateral oophorectomy 3. Must have negative serum/urine pregnancy test 4. If of reproductive age, must practice effective contraceptive method Exclusion Criteria: 1. Patient has multiple severe neurologic deficits per physician assessment 2. Patient has diffuse systemic disease without reasonable systemic therapy options 3. Patient is unable to undergo MRI brain and spine with gadolinium contrast 4. Prior radiation that would preclude development of a treatment plan that respects normal tissue constraints 5. Pregnant or lactating women 6. Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leptomeningeal metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leptomeningeal metastasis

Contacts and locations

Locations

  • NYU Langone Health

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.